TNGX as reported
Tango Therapeutics, Inc. reported $60M of revenue over the trailing twelve months, +146% on the year before. 8 reported series are charted on this page, each one as filed.
$60M
Revenue, trailing twelve months · to Q2 2026 · +146% against the twelve months before
- Net Income
- −$124M
Net Income · −15% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$144M
Free Cash Flow · −3.3% year on year · trailing twelve months to Q2 2026
- Op Margin
- −761%
Op Margin · trailing twelve months to Q3 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $60M | +146% | Q2 2026 |
| Net Income | −$124M | −15% | Q2 2026 |
| EPS | −$0.86 | −35% | Q2 2026 |
| Op Margin | −761% | n/a | Q3 2025 |
| Net Margin | −712% | n/a | Q3 2025 |
| ROE | −33% | n/a | Q2 2026 |
| ROA | −27% | n/a | Q2 2026 |
| Free Cash Flow | −$144M | −3.3% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Tango Therapeutics, Inc. (TNGX) - Revenue & ProfitRevenue & ProfitTango Therapeutics, Inc. (TNGX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com